Background: Colorectal cancer affects a large number of patients worldwide, with numerous factors being involved in its etiopathogenesis and chronic inflammation playing an essential role in tumor development. In this study, we analyzed and compared several markers of inflammation that are relatively easy to obtain for a rapid and accurate diagnosis and prognosis.Methods: This study included 219 patients diagnosed with colorectal cancer, analyzing the inflammation scores derived from their blood cells and inflammatory circulating proteins. These inflammatory markers are neutrophil-to-lymphocyte ratio—NLR; platelet-to-lymphocyte ratio—PLR; lymphocyte-to-monocyte ratio—LMR; systemic immune inflammation index—SII; systemic inflammatory response index—SIRI; aggregate index of systemic inflammation—AISI; derived neutrophil-to-lymphocyte ratio—dNLR; C-reactive protein-to-albumin ratio—CAR; and fibrinogen-to-albumin ratio—FAR. In the analysis of patients with colorectal cancer, we have also introduced two new recently developed inflammatory markers: the cumulative inflammatory index (IIC) and the ratio between the mean corpuscular volume and lymphocytes (MCVL). This study aimed to correlate the inflammatory markers’ levels with the colorectal cancer diagnostic stage, the tumor and clinical characteristics of the colorectal cancer patients, and 36 months’ survival time and to evaluate the diagnostic and prognostic capacity and accuracy of these inflammatory markers in this type of cancer.Results: We showed that the levels of the analyzed inflammation markers correlate with the TNM stage, the tumor pathological differentiation grade, the age and gender of the patients, and overall survival, with their increased levels being associated with a lower survival rate.Conclusions: The analyzed markers, which are easy to perform right from the patient’s admission, can be helpful both in diagnosis and, mostly, in prognosis, sustaining the role of inflammation in cancer. By comparing them, we showed which one can be useful for increased sensitivity and specificity in the diagnosis and prognosis of colorectal cancer patients.
背景：结直肠癌在全球范围内影响大量患者，其病因发病机制涉及多种因素，其中慢性炎症在肿瘤发展中起着至关重要的作用。本研究旨在分析并比较几种相对易于获取的炎症标志物，以期实现快速、准确的诊断与预后评估。 方法：本研究纳入219例确诊为结直肠癌的患者，分析其血细胞及循环炎症蛋白衍生的炎症评分。这些炎症标志物包括：中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）、全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）、全身炎症综合指数（AISI）、衍生中性粒细胞与淋巴细胞比值（dNLR）、C反应蛋白与白蛋白比值（CAR）以及纤维蛋白原与白蛋白比值（FAR）。在结直肠癌患者分析中，我们还引入了两种新近开发的炎症标志物：累积炎症指数（IIC）和平均红细胞体积与淋巴细胞比值（MCVL）。本研究旨在探究炎症标志物水平与结直肠癌诊断分期、肿瘤及临床特征以及36个月生存期的相关性，并评估这些炎症标志物在该类癌症中的诊断与预后能力及准确性。 结果：研究表明，所分析的炎症标志物水平与TNM分期、肿瘤病理分化程度、患者年龄和性别以及总生存期相关，其水平升高与较低生存率相关。 结论：这些分析标志物在患者入院时即可便捷检测，不仅有助于诊断，更在预后评估中具有重要价值，进一步支持了炎症在癌症中的作用。通过比较这些标志物，我们明确了哪些指标在提高结直肠癌患者诊断和预后的敏感性与特异性方面更具实用价值。
肿瘤(癌症)患者之家